573 terminated. 573 Phase 2, 189 Phase 1, 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 573 | Terminated 573 |
| Phase 1 | 189 | Terminated 189 |
| Phase 3 | 12 | Terminated 12 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1 / Phase 2 | Terminated | Servier Bio-Innovation LLC | 13 | 2025-02-25 | 2026-03-30 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML Luveltamab tazevibulin - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | Sutro Biopharma, Inc. | 1 | 2024-12-04 | 2026-10-13 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Sanofi | 7 | 2024-08-13 | 2026-10-19 |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | Terminated | Ryvu Therapeutics SA | 62 | 2024-01-23 | 2026-09-16 |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant VCAR33 - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Terminated | Vor Biopharma | 38 | 2023-12-11 | 2025-07-29 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia Clofarabine, Fludarabine, Hematopoietic Cell Transplantation - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 23 | 2023-08-11 | 2026-08-06 |
| A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia GDX012, Chemotherapy Agents - Leukemia | Phase 1 / Phase 2 | Terminated | Takeda | 16 | 2023-07-11 | 2026-09-25 |
| Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy Selinexor, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Adult | Phase 1 / Phase 2 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 6 | 2023-05-05 | 2025-05-30 |
| Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant Venetoclax, Decitabine, Cedazuridine - Recurrent Acute Myeloid Leukemia | Phase 2 | Terminated | Sanjay Mohan | 1 | 2023-04-13 | 2026-01-09 |
| Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL CB-103, Venetoclax - Leukemia, Lymphoblastic, Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-04-06 | 2025-11-26 |
| A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant Siremadlin - Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 8 | 2023-02-23 | 2025-05-16 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) ZN-d5 ZN-c3, ZN-c3 - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 40 | 2022-12-01 | 2024-09-19 |
| Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax Pirtobrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2022-11-16 | 2025-12-15 |
| Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation | Phase 2 | Terminated | Kite, A Gilead Company | 19 | 2022-11-01 | 2026-03-10 |
Showing 20 of 573. Sign in to see all of them.
Leukemia, Myeloid, Acute (239) · Leukemia, Lymphocytic, Chronic, B-Cell (156) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (131) · Myelodysplastic Syndromes (129) · Lymphoma, Non-Hodgkin (80) · Lymphoma (77) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (72) · Lymphoma, Large B-Cell, Diffuse (51) · Lymphoma, Follicular (50) · Multiple Myeloma (49) · Recurrence (49) · Lymphoma, Mantle-Cell (46) · Hodgkin Disease (43) · Burkitt Lymphoma (40)
Hemic and Lymphatic Diseases (573) · Neoplasms by Histologic Type (572) · Hematologic Diseases (563) · Neoplasms (553) · Immune System Diseases (319) · Immunoproliferative Disorders (315) · Leukemia, Myeloid (311) · Lymphatic Diseases (310) · Lymphoproliferative Disorders (308) · Pathological Conditions, Signs and Symptoms (291) · Pathologic Processes (289) · Disease Attributes (281) · Leukemia, Lymphoid (275) · Chronic Disease (251)
Cyclophosphamide (67) · Cytarabine (64) · fludarabine phosphate (53) · fludarabine (52) · Rituximab (49) · Azacitidine (39) · Methotrexate (38) · venetoclax (33) · Busulfan (30) · Whole-Body Irradiation (30) · Filgrastim (28) · Tacrolimus (28) · Antilymphocyte Serum (25) · Mycophenolic Acid (23) · Granulocyte Colony-Stimulating Factor (22)
M.D. Anderson Cancer Center (72) · National Cancer Institute (NCI) (30) · Masonic Cancer Center, University of Minnesota (23) · Fred Hutchinson Cancer Center (19) · Gilead Sciences (10) · Novartis Pharmaceuticals (9) · OHSU Knight Cancer Institute (9) · TG Therapeutics, Inc. (8) · Washington University School of Medicine (8) · H. Lee Moffitt Cancer Center and Research Institute (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · St. Jude Children's Research Hospital (7) · Sanofi (6) · Bristol-Myers Squibb (5) · Emory University (5)
United States (468) · France (52) · Germany (45) · Italy (43) · Spain (38) · Canada (32) · United Kingdom (32) · Australia (20) · Belgium (20) · Netherlands (20) · South Korea (15) · Poland (14) · Austria (11) · China (11) · Czechia (10)
Courtney DiNardo, MD (5) · Jorge Cortes, MD (5) · Elias Jabbour (3) · Guillermo Garcia-Manero, MD (3) · Januario Castro, M.D. (3) · Noelle Frey, MD (3) · Srdan Verstovsek (3) · Stephen Anthony, DO (3)
PMID 35622074, PMID 26472751, PMID 28835440, PMID 30885996, PMID 31527168, PMID 34398557, PMID 41671463, PMID 12011123, PMID 16651647, PMID 17579184, PMID 19139736, PMID 19179301, PMID 19826119, PMID 20307284, PMID 21145590, PMID 21403127, PMID 21874061, PMID 22080968, PMID 22133771, PMID 22267607, PMID 22289993, PMID 22430088, PMID 22766223, PMID 22987312, PMID 23233571, PMID 23265768, PMID 23426279, PMID 23426943, PMID 23620574, PMID 23782682, PMID 23949430, PMID 24081577, PMID 24200998, PMID 24241210, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24719405, PMID 24891274, PMID 24925211, PMID 24990615, PMID 25127392, PMID 25130401, PMID 25441108, PMID 25596730, PMID 25696919, PMID 25878120, PMID 25939707, PMID 26053664
P30CA015704 (10), 2018 (9), P30CA016672 (7), 2023 (5), P30CA015083 (5), 2009 (4), 2016 (4), 2019 (4), P01CA018029 (4), P50CA171963 (4), 2008 (3), 2014 (3), 2015 (3), 2017 (3), N01CM17003 (3)